Lesions Clinical Trial
Official title:
Prospective Evaluation of Tumor Angiogenesis in Endocrine Neoplasms
NCT number | NCT00923780 |
Other study ID # | 070060 |
Secondary ID | 07-C-0060 |
Status | Completed |
Phase | N/A |
First received | June 17, 2009 |
Last updated | June 30, 2017 |
Start date | January 5, 2007 |
Verified date | September 28, 2009 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Background:
- Tumors depend on blood vessels to provide the nourishment that allows them to grow.
- Thyroid, parathyroid, adrenal gland and pancreatic neuroendocrine tumors are among the
tumors that contain the most blood vessels. Thus, endocrine tumors are important for the
study of new blood vessel formation in tumors.
Objectives:
-To obtain tissues from endocrine tumors for examination to determine how they differ from
normal tissue.
Eligibility:
-Patients who are scheduled for surgery to remove an endocrine tumor, those in or around the
thyroid, parathyroid, adrenal gland, pancreas, or any neuroendocrine tissue.
Design:
- Tissues will be obtained from patients during surgery to remove thyroid, parathyroid,
adrenal, pancreas, or neuroendocrine tumors.
- About 400 patients will be enrolled in the study over a period of 5 years.
Status | Completed |
Enrollment | 400 |
Est. completion date | |
Est. primary completion date | September 28, 2009 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
- INCLUSION CRITERIA: - Patients referred to the Endocrine Consult Service with radiographic evidence of, biochemical evidence of, or histologically/cytologically proven, endocrine neoplasms, including lesions of the thyroid, parathyroid, adrenal, extra-adrenal endocrine rests, paragangliomas, neuroblastomas and pancreas. - Patients must have an ECOG performance score of 0-2. - Patients must have laboratory and physical examination parameters within acceptable limits by standard of practice guidelines prior to biopsy or surgery. - Patients undergoing treatment for their neoplasm may be eligible. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 1999 Apr 30;284(5415):808-12. — View Citation
Libutti SK, Crabtree JS, Lorang D, Burns AL, Mazzanti C, Hewitt SM, O'Connor S, Ward JM, Emmert-Buck MR, Remaley A, Miller M, Turner E, Alexander HR, Arnold A, Marx SJ, Collins FS, Spiegel AM. Parathyroid gland-specific deletion of the mouse Men1 gene results in parathyroid neoplasia and hypercalcemic hyperparathyroidism. Cancer Res. 2003 Nov 15;63(22):8022-8. — View Citation
Mazzanti C, Zeiger MA, Costouros NG, Umbricht C, Westra WH, Smith D, Somervell H, Bevilacqua G, Alexander HR, Libutti SK. Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res. 2004 Apr 15;64(8):2898-903. Erratum in: Cancer Res. 2004 Jul 15;64(14):5028. Costourous N [corrected to Costouros NG]. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02979509 -
Evaluation of Diagnostic Yield of EUS-Guided Tissue Sampling
|
||
Completed |
NCT00861172 -
Longitudinal (Weekly) Follow-up of Active Plaques in Multiple Sclerosis With 3 Teslas Multi-modality MRI Using Diffusion, Perfusion, Venography and Proton Spectroscopy
|
N/A |